Pediatric hospital healthcare workers and pertussis; a seroprevalence study

Background. This study aimed to assess pertussis seroprevalence among healthcare workers (HCWs) of a university children’s hospital and to determine their opinions on whether to get the pertussis vaccine booster dose in adulthood. Methods. This cross-sectional study was carried out between January 2018 and March 2019. Data recording forms were filled by the face to face interview method. Anti-pertussis toxin IgG (Anti-PT IgG) antibody levels were determined quantitatively from the serum samples using a commercial enzyme-linked immunosorbent assay (ELISA) kit. Anti-PT IgG results were interpreted according to World Health Organization (WHO) recommendations. Results. Of the 169 HCWs included in the study, 67 (39.6%) were seronegative and susceptible to pertussis. Seropositivity was significantly higher among HCWs who worked 40–80 hours per week. Thirty-six (21.3%) HCWs had high anti-PT IgG levels, indicating recent infection in the past few years. High-level positivity was significantly more common among HCWs using macrolide antibiotics due to prolonged cough. Anti-PT IgG levels of three (1.8%) were compatible with acute infection and they were not followed up with suspicion of whooping cough and were not isolated. While 125 (74.0%) of the participants said they could get the pertussis vaccine booster dose, only three (1.8%) had done so. Conclusions. The fact that 39.6% of HCWs were seronegative, emphasized the need for the pertussis booster dose. More than 20% of HCWs have had the acute infection without pertussis diagnosis in the past few years. Adult vaccination awareness in HCWs has not yet created a change in behavior. The high rate of seropositivity in macrolide users also shows that we cannot prevent its spread despite treatment. These findings highlight the fact that pertussis can occur in adult age groups and that eradication cannot be achieved without effective adult immunization and surveillance.

PDF

___

1. World Health Organization (WHO). The immunological basis for immunization series - module 4: pertussis, update 2017. Available at: https://apps.who.int/iris/handle/10665/259388. (Accessed on May 12, 2020).

2. Hoffait M, Hanlon D, Benninghoff B Calcoen S. Pertussis knowledge, attitude and practices among European health care professionals in charge of adult vaccination. Hum Vaccin 2011; 7: 197-201.

3. Strebel P, Nordin J, Edwards K, et al. Population‐ based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001; 183: 1353-1359.

4. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis 1999; 28(Suppl 2): S112-S117.

5. Kurugol Z. Türkiye’de boğmaca epidemiyolojisi: pekiştirme aşı dozları gerekli mi? Çocuk Enfeksiyon Dergisi 2009; 3: 14-18.

6. Pertussis vaccines: WHO position paper – August 2015. Available: https://www.who.int/wer/2015/ wer9035.pdf?ua=1. (Accessed on May 12, 2020).

7. Urbiztondo L, Broner S, Costa J, et al; The Working Group For The Study Of The Immune Status In Health Care. Seroprevalence study of B. pertussis infection in health care workers in Catalonia, Spain. Hum Vaccin Immunother 2015; 11: 293-297.

8. Sandora TJ, Gidengil CA, Lee GM. Pertussis vaccination for health care workers. Clin Microbiol Rev 2008; 21: 426-434.

9. Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2018; 67: 1-44.

10. World Health Organization, Study on global ageing and adult health (SAGE) pertussis working group. Available at: https://www.who.int/immunization/ sage/meetings/2014/april/1_Pertussis_background_ FINAL4_web.pdf?ua (Accessed on May 12, 2020).

11. Esen B, Coplu N, Kurtoglu D, Gozalan A, Akin L. Prevalence of high antibody titers of pertussis in Turkey: reflection of circulating microorganism and a threat to infants. J Clin Lab Anal 2007; 21: 154-161.

12. Duranoglu L, Sonmez C, Vurucu S, et al. Evaluation of pertussis immunity status in schoolchildren immunized with whole-cell vaccine. Epidemiol Infect 2010; 138: 299-303.

13. Vatansever U, Coplu N, Oner N, et al. Seroprevalance of Bordetella pertussis antibodies among healthy adolescent girls in Edirne. Swiss Med Wkly 2005; 135: 531-536.

14. Tanriover MD, Soyler C, Ascioglu S, Cankurtaran M, Unal S. Low seroprevalance of diphtheria, tetanus and pertussis in ambulatory adult patients: the need for lifelong vaccination. Eur J Intern Med 2014; 25: 528-532.

15. EUROIMMUN. Anti-Bordetella pertussis toxin ELISA (IgG). Available at: https://www.euroimmun. com/documents/Indications/Infections/Bordetella/ EI_2050_D_UK_A.pdf (Accessed on May 12, 2020)

16. Hashemi SH, Ranjbar M, Hajilooi M, Seif-Rabiei MA, Bolandi M, Moghimi J. Seroprevalence of Immunoglobulin G antibodies against pertussis toxin among asymptomatic medical students in the west of Iran: a cross sectional study. BMC Infect Dis 2009; 9: 58.

17. Higa F, Haranaga S, Tateyama M, et al. Assessment of serum anti-Bordetella pertussis antibody titers among medical staff members. Jpn J Infect Dis 2008; 61: 371-374.

18. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005; 24(Suppl 5): S58-S61.

19. Cevik M, Beyazova U, Aral AL, et al. Seroprevalence of IgG antibodies against Bordetella pertussis in healthy individuals aged 4-24 years in Turkey. Clin Microbiol Infect 2008; 14: 388-390.

20. Türkoglu E, Sönmez C, Kurugöl Z, Çöplü N, Koturoğlu G. Pertussis serosurveillance study in Izmir, Turkey. J Trop Pediatr 2015; 61: 32-36.

21. Cunegundes KS, de Moraes-Pinto MI, Takahashi TN, Kuramoto DA, Weckx LY. Bordetella pertussis infection in paediatric healthcare workers. J Hosp Infect 2015; 90: 163-166.

22. Rodríguez de la Pinta ML, Castro Lareo MI, Ramon Torrell JM, et al. Seroprevalence of pertussis amongst healthcare professionals in Spain. Vaccine 2016; 34: 1109-1114

23. Riffelmann M, Koesters K, Saemann-Ischenko G, Schmitt HJ, Wirsing von Koenig CH. Antibodies to pertussis antigens in pediatric health care workers. Pediatr Infect Dis J 2002; 21: 381-383.

24. Faruque MO, Senanayake S, Meyer AD, Dear KB, et al. Emergency department staff and susceptibility to pertussis: a seroprevalence study. Emerg Med Australas 2008; 20: 45-50.

25. Choi WS, Kim SH, Park DW. Seroprevalence of pertussis in healthcare workers without adult pertussis vaccine use at a University Hospital in Korea. J Korean Med Sci 2018; 35: e321.

26. Naeini AE, Zaman N, Khorvash F, et al. Does working in hospital increases seroprevalence and carrier state against Bordetella pertussis? Adv Biomed Res 2015; 4: 194.

27. Koivisto K, Puhakka L, Lappalainen M, Blomqvist S, Saxén H, Nieminen T. Immunity against vaccinepreventable diseases in Finnish pediatric healthcare workers in 2015. Vaccine 2017; 35: 1608-1614.

28. Ben Fraj I, Smaoui H, Zghal M, Sassi O, Guiso N, Kechrid A. Seroprevalence of pertussis among healthcare workers: a cross-sectional study from Tunisia. Vaccine 2019; 37: 109-112.

29. Kim S, Oh H, Ham O, Chung MH, Seo W. Susceptibility and factors of pertussis vaccination adherence in Korean health care workers. Am J Health Behav 2004; 34: 45-53.

30. Maltezou HC, Poland GA. Vaccination policies for healthcare workers in Europe. Vaccine 2014; 32: 4876-4880.

31. Randi BA, Sejas ONE, Miyaji KT, et al. A systematic review of adult tetanus- diphtheria-acellular (Tdap) coverage among healthcare workers. Vaccine 2019; 37: 1030-1037.

32. Top KA, Halperin BA, Baxendale D, MacKinnonCameron D, Halperin SA. Pertussis immunization in paediatric healthcare workers: knowledge, attitudes, beliefs, and behaviour. Vaccine 2010; 28: 2169-2173.